Related Experiment Video
Updated: May 10, 2026

Enrichment of mRNA and Bisulfite-mRNA Library Preparation for Next-Generation Sequencing
Published on: July 7, 2023
LINE1 RNA demethylation sensitizes cancer cells to PARPi through global chromatin remodeling
Zihong Kang1,2, Ruimeng Li3, Lei Xu4
1State Key Laboratory of Gene Function and Modulation Research, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing, 100871, China.
Background:
Repression of DNA damage repair by PARP inhibitors (PARPi) has shown great efficacy in cancer treatment. However, therapy resistance remains a significant clinical challenge.
Results:
Here, we demonstrate that the N6-methyladenosine (m6A) modification of long interspersed nucleotide element-1 (LINE1, or L1) facilitates DNA damage repair in cancer cells, whereas removal of L1 m6A modifications enhances the sensitivity of both BRCA-wild-type and BRCA-mutant cells to PARPi. Specifically, following olaparib treatment, METTL3 accumulates on chromatin at non-damage sites, which results in increased chromatin accessibility. Knockdown of METTL3 or removal of m6A on L1 RNAs increases H3K9me3 levels, leading to reduced chromatin accessibility. This, in turn, inhibits DNA end resection at damage sites and prevents PARP1 dissociation, ultimately impairing homologous recombination repair and enhancing tumor sensitivity to PARPi.
Conclusions:
Our findings unveil a novel regulatory mechanism of L1 m6A that governs the DNA damage repair response, providing a potential strategy of targeting METTL3 in combination with PARPi for cancer therapy.
Insights
Targeting N6-methyladenosine (m6A) modification on LINE1 (L1) retrotransposons can overcome PARP inhibitor (PARPi) resistance in cancer. Removing L1 m6A enhances cancer cell sensitivity to PARPi by impairing DNA repair.
Area of Science:
- Cancer Biology
- Epigenetics
- DNA Damage Response
Background:
- PARP inhibitors (PARPi) are effective cancer treatments, but therapy resistance is a major obstacle.
- Understanding resistance mechanisms is crucial for improving cancer therapy outcomes.
Purpose of the Study:
- To investigate the role of N6-methyladenosine (m6A) modification in LINE1 (L1) retrotransposons in cancer therapy resistance.
- To explore novel strategies for overcoming PARPi resistance.
Main Methods:
- Analysis of m6A modification on L1 retrotransposons in cancer cells.
- Investigating the impact of METTL3, an m6A writer, on chromatin accessibility and DNA repair.
- Assessing the sensitivity of BRCA-wild-type and BRCA-mutant cells to PARPi following modulation of L1 m6A.
Main Results:
- m6A modification of L1 facilitates DNA damage repair in cancer cells.
- Removal of L1 m6A modifications increases sensitivity to PARPi in both BRCA-wild-type and BRCA-mutant cells.
- METTL3 accumulation on chromatin increases accessibility; its knockdown or L1 m6A removal reduces accessibility, impairs DNA repair, and enhances PARPi sensitivity.
Conclusions:
- L1 m6A modification is a novel regulator of the DNA damage repair response.
- Targeting METTL3 in combination with PARPi presents a potential therapeutic strategy for cancer treatment.
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
piRNA - Piwi-interacting RNAs
Experimental RNAi
Abnormal Proliferation

